Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
ERADAL-HF is a double blinded, multi-centre, prospective, randomized, three arm study,
enrolled ambulatory patients with chronic heart failure [New York Heart Association (NYHA)
class II/III], with iron deficiency [defined as ferritin <100 ng/mL, or ferritin 100-300
ng/mL if transferrin saturation (TSAT) <20%] and haemoglobin (Hb) < 15 g/dL. Patients were
randomized 1:1:1 to treatment into three arms: a first group treated with intravenous iron
supplementation, a second treated by intramuscular iron supplementation and the third one
which have received placebo. These patients were followed-up during a period of 04 weeks.
The aim of this study is to assess the short term effect of parenteral iron supplementation
on exercise tolerance and oxidative stress in patients with stable chronic heart failure and
iron deficiency
Phase:
Phase 4
Details
Lead Sponsor:
CN NGANOU-GNINDJIO, MD, MSc
Treatments:
Ferric Compounds Ferric Oxide, Saccharated Iron Teferrol